Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MAAQ
Mana Capital Acquisition
$3.95
-6.8%
$1.18
$5.35
$10.25
$32.09MN/A33,075 shs68,563 shs
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
$7.98
+1.1%
$7.71
$2.10
$23.01
$8.37M0.48976,215 shs37,450 shs
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
$11.57
+0.2%
$7.97
$2.70
$18.00
$31.31M0.11991,974 shs143,792 shs
Scilex Holding stock logo
SCLX
Scilex
$4.85
+6.6%
$6.29
$3.60
$80.50
$33.72M1.159,678 shs109,611 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MAAQ
Mana Capital Acquisition
0.00%-10.63%+716.12%+690.00%+475.97%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
+1.14%-4.20%-5.56%+77.33%+51.71%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
+0.17%+1.58%+63.42%+100.52%+1,156,999,900.00%
Scilex Holding stock logo
SCLX
Scilex
+6.59%-3.00%+3.85%-48.68%-87.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.3107 of 5 stars
0.04.00.00.00.01.70.0
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Scilex Holding stock logo
SCLX
Scilex
1.5263 of 5 stars
3.32.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
0.00
N/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
0.00
N/AN/AN/A
Scilex Holding stock logo
SCLX
Scilex
2.60
Moderate Buy$455.009,281.44% Upside

Current Analyst Ratings Breakdown

Latest PRTG, MAAQ, SCLX, and QNTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/11/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/2/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$770.00 ➝ $630.00
2/28/2025
Scilex Holding stock logo
SCLX
Scilex
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$770.00 ➝ $770.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/A$13.76 per share0.58$3.74 per shareN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/A$21.29 per shareN/A
Scilex Holding stock logo
SCLX
Scilex
$50.71M0.66N/AN/A($1.10) per share-4.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
-$75.34M-$41.65N/AN/AN/A-342.34%-196.47%5/30/2025 (Estimated)
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$17.90M-$15.98N/AN/AN/AN/A-84.21%-62.63%8/13/2025 (Estimated)
Scilex Holding stock logo
SCLX
Scilex
-$114.33M-$29.02N/AN/AN/A-159.10%N/A-93.65%8/12/2025 (Estimated)

Latest PRTG, MAAQ, SCLX, and QNTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million
3/28/2025Q4 2024
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/AN/AN/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/A
Scilex Holding stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MAAQ
Mana Capital Acquisition
N/AN/AN/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
N/A
3.08
3.08
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A
3.76
3.76
Scilex Holding stock logo
SCLX
Scilex
N/A
0.14
0.13

Institutional Ownership

CompanyInstitutional Ownership
MAAQ
Mana Capital Acquisition
68.44%
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
13.36%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
1.24%
Scilex Holding stock logo
SCLX
Scilex
69.67%

Insider Ownership

CompanyInsider Ownership
MAAQ
Mana Capital Acquisition
N/A
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
42.07%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
8.53%
Scilex Holding stock logo
SCLX
Scilex
7.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable
Portage Biotech Inc. stock logo
PRTG
Portage Biotech
61.05 million608,000Optionable
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A2.71 million1.76 millionN/A
Scilex Holding stock logo
SCLX
Scilex
806.95 million222.07 millionOptionable

Recent News About These Companies

Scilex treatment of pericarditis granted FDA orphan designation
Scilex confirms FDA awards orphan drug designation for colchicine
Scilex announces 1-for-35 reverse stock split
Scilex regains compliance with Nasdaq listing rules

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mana Capital Acquisition NASDAQ:MAAQ

$3.95 -0.29 (-6.84%)
As of 05/23/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Portage Biotech stock logo

Portage Biotech NASDAQ:PRTG

$7.98 +0.09 (+1.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.86 -0.13 (-1.57%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.

Quantum Biopharma stock logo

Quantum Biopharma NASDAQ:QNTM

$11.57 +0.02 (+0.17%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$11.60 +0.03 (+0.26%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Scilex stock logo

Scilex NASDAQ:SCLX

$4.85 +0.30 (+6.59%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.87 +0.02 (+0.41%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.